These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

635 related articles for article (PubMed ID: 18330822)

  • 1. An increased risk for non allo-immunization related intrauterine fetal death in RhD-negative patients.
    Ben-David G; Sheiner E; Levy A; Erez O; Mazor M
    J Matern Fetal Neonatal Med; 2008 Apr; 21(4):255-9. PubMed ID: 18330822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevention of fetomaternal rhesus-D allo-immunization. Practical aspects].
    Cortey A; Brossard Y
    J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S123-1S130. PubMed ID: 16495838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative.
    Chilcott J; Tappenden P; Lloyd Jones M; Wight J; Forman K; Wray J; Beverley C
    BJOG; 2004 Sep; 111(9):903-7. PubMed ID: 15327602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Epidemiology of anti-D allo-immunization during pregnancy].
    Branger B; Winer N
    J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S87-1S92. PubMed ID: 16495833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RhD haemolytic disease of the fetus and the newborn.
    Urbaniak SJ; Greiss MA
    Blood Rev; 2000 Mar; 14(1):44-61. PubMed ID: 10805260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The importance of antenatal immunoprophylaxis for prevention of hemolytic disease of the fetus and newborn].
    Starcević M; Mataija M; Sović D; Dodig J; Matijević R; Kukuruzović M
    Acta Med Croatica; 2011 Mar; 65(1):49-54. PubMed ID: 21568074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prevention of fetomaternal rhesus-D allo-immunization. Perspectives].
    Cortey A; Brossard Y; Beliard R; Bourel D
    J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S119-1S122. PubMed ID: 16495837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An audit of the investigation and use of anti-D immunoglobulin prophylaxis in Tayside.
    Rennie I; Smith A; Smith R; Rawlinson PS; Clark P
    Health Bull (Edinb); 2001 May; 59(3):150-4. PubMed ID: 12664753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and benefits of non-invasive fetal RhD determination.
    Teitelbaum L; Metcalfe A; Clarke G; Parboosingh JS; Wilson RD; Johnson JM
    Ultrasound Obstet Gynecol; 2015 Jan; 45(1):84-8. PubMed ID: 25380024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A curious case of anti-D antibody titer.
    Hensley JG; Coughlin KP; Klein LL
    J Midwifery Womens Health; 2009; 54(6):497-502. PubMed ID: 19879523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consequences of being Rhesus D immunized during pregnancy and how to optimize new prevention strategies.
    Tiblad E; Westgren M; Pasupathy D; Karlsson A; Wikman AT
    Acta Obstet Gynecol Scand; 2013 Sep; 92(9):1079-85. PubMed ID: 23750781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Advantages of preventing Rh isoimmunization].
    Mikulandra F; Merlak I; Perisa M; Kapitanović Z; Barbetti V; Kimer M; Glavadanović N
    Jugosl Ginekol Perinatol; 1985; 25(1-2):29-34. PubMed ID: 3003466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adverse effects and patient information].
    Cortey A; Brossard Y
    J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S112-1S118. PubMed ID: 16495836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is it necessary to administer anti-D to prevent RhD immunization after the transfusion of RhD-positive platelet concentrates?
    Atoyebi W; Mundy N; Croxton T; Littlewood TJ; Murphy MF
    Br J Haematol; 2000 Dec; 111(3):980-3. PubMed ID: 11122163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Transvaginal bleeding in pregnancy, as risk factor of Rhesus-D antigen isoimmunization].
    Hernández-Andrade E; Ahued-Ahued JR
    Salud Publica Mex; 2003; 45(6):492-6. PubMed ID: 14974293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fetal RhD genotyping: a more efficient use of anti-D immunoglobulin.
    Daniels G; Finning K; Martin P; Summers J
    Transfus Clin Biol; 2007 Dec; 14(6):568-71. PubMed ID: 18436463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy.
    Koelewijn JM; de Haas M; Vrijkotte TG; Bonsel GJ; van der Schoot CE
    Transfusion; 2008 Aug; 48(8):1721-9. PubMed ID: 18507749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Report of the first nationally implemented clinical routine screening for fetal RHD in D- pregnant women to ascertain the requirement for antenatal RhD prophylaxis.
    Clausen FB; Christiansen M; Steffensen R; Jørgensen S; Nielsen C; Jakobsen MA; Madsen RD; Jensen K; Krog GR; Rieneck K; Sprogøe U; Homburg KM; Grunnet N; Dziegiel MH
    Transfusion; 2012 Apr; 52(4):752-8. PubMed ID: 21995641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do Rh-negative women with first trimester spontaneous abortions need Rh immune globulin?
    Hannafin B; Lovecchio F; Blackburn P
    Am J Emerg Med; 2006 Jul; 24(4):487-9. PubMed ID: 16787810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Value of RHD fetal genotyping in the prevention of anti-D immunization].
    Brossard Y; Sender A; Cartron JP; Huchet J; Pinon F; Blot P; David G
    Bull Acad Natl Med; 2001; 185(2):329-36. PubMed ID: 11474588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.